17 reports of this reaction
5.2% of all BENZETHONIUM CHLORIDE reports
#4 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT DECREASED is the #4 most commonly reported adverse reaction for BENZETHONIUM CHLORIDE, manufactured by McKesson. There are 17 FDA adverse event reports linking BENZETHONIUM CHLORIDE to THERAPEUTIC PRODUCT EFFECT DECREASED. This represents approximately 5.2% of all 326 adverse event reports for this drug.
Patients taking BENZETHONIUM CHLORIDE who experience therapeutic product effect decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT DECREASED is moderately reported among BENZETHONIUM CHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to therapeutic product effect decreased, the following adverse reactions have been reported for BENZETHONIUM CHLORIDE:
The following drugs have also been linked to therapeutic product effect decreased in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT DECREASED has been reported as an adverse event in 17 FDA reports for BENZETHONIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT DECREASED accounts for approximately 5.2% of all adverse event reports for BENZETHONIUM CHLORIDE, making it a notable side effect.
If you experience therapeutic product effect decreased while taking BENZETHONIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.